Clinical Trials Logo

Cancer clinical trials

View clinical trials related to Cancer.

Filter by:
  • Recruiting  
  • Page 1 ·  Next »

NCT ID: NCT03247283 Recruiting - Cancer Clinical Trials

Pharmacokinetics and Metabolism Study in Healthy Male Participants

Start date: July 19, 2017
Phase: Phase 1
Study type: Interventional

Phase 1 Phamacokinetic and metabolism study of BMS-986205 in healthy males

NCT ID: NCT03244202 Recruiting - Cancer Clinical Trials

Evaluation of a Decision Aid for Incidental Genomic Findings

Start date: September 12, 2016
Phase: N/A
Study type: Interventional

Health care providers (HCP) are increasingly using genomic sequencing (GS) to target treatment for patients. However, GS may incidentally reveal inherited risks for thousands of current and future diseases. Guidelines recommend HCP inform patients of incidental GS results. No decision aid (DA) exists to guide patients' decisions about which incidental GS results they wish to learn. This study will evaluate whether the DA followed by genetic counselling (GC) reduces decisional conflict compared to GC alone in a randomized controlled trial (RCT) with 128 patients with a family history of cancer, who have had a negative genetic test and may eligible for GS. A qualitative component with a subset of participants (n=40) will explore patients' preferences for the types of incidental results they wish to receive and their decision making process.

NCT ID: NCT03235427 Recruiting - Breast Cancer Clinical Trials

The CAROLE (CArdiac Related Oncologic Late Effects) Study

Start date: June 27, 2017
Phase: N/A
Study type: Observational

CAROLE seeks to evaluate the relationship between chest Radiation Therapy and coronary artery disease. The purpose of CAROLE is to check the heart health of women who received breast cancer treatments in the past and protect them from future heart disease.

NCT ID: NCT03231891 Recruiting - Cancer Clinical Trials

Inherited CAncer REgistry

Start date: February 27, 2017
Phase: N/A
Study type: Observational [Patient Registry]

The purpose of the Inherited CAncer REgistry (ICARE) Initiative is to provide individuals interested in participating in studies focused on inherited cancer predisposition the opportunity to enroll in a research registry. Efforts through the registry include, but are not limited to, contribution of data to observational studies, targeted gene-specific studies, and education and outreach efforts for both participants and recruiting healthcare providers. Participants are given the opportunity to learn about and participate in other efforts for which they may be eligible. All participants and recruiting healthcare providers receive educational newsletters twice per year which contain research and clinical updates in the field of cancer genetics. Providers who recruit patients can also access monthly web-based genetics case conferences which focus on different topics each month and are generally attended by a guest expert who provides background information on the topic as well as comments on the case presentations. Participation in ICARE involves completion of an informed consent form, baseline questionnaire, follow-up questionnaires every two years, and medical record/tumor releases, as applicable. There is no cost to participate and all correspondence can be facilitated through phone, email, or mail. Enrollment can be completed either through a traditional paper-based consenting method (i.e. postal mail) or through the online enrollment option available on the ICARE website ( If you are a patient interested in learning more or a provider interested in recruiting to ICARE, please visit our website where you may complete an online contact form requesting a study team member contact you.

NCT ID: NCT03230305 Recruiting - Cancer Clinical Trials

Elderly CAncer Patient: Qualitative and Quantitative Factors of Inclusion Failure in Clinical Trials

Start date: April 12, 2017
Phase: N/A
Study type: Observational

The transposition of the results of biomedical research to medical management of patients in real-life setting depends highly from patient's selection. In Europe and the United States, the majority of cancers occur after 65 years. In France, 45% of cancers diagnosed in 2012 were after 70 years or 158,722 in absolute value. In this context, the median age at diagnosis was 72 years old. Disease particularly affecting the elderly, cancer is also characterized by the importance of biomedical research devoted to it. Despite the dynamism of the research activity in oncology and therefore the number of affected patients, the elderly are paradoxically sparsely included in clinical trials. Numerous studies have focused in recent years, to identify possible causes of under-representation of elderly patients in clinical trials but most of them focused on eligibility criteria and few on barriers related to non-invitation or non-inclusion in eligible patients. We postulate that a qualitative survey based on an structured epidemiological device will able to objective evidences of reasons related to the patient, his/her familial caregivers, his/her physician and the clinical center organization for participating or not to a clinical trial and the interrelations between the identified reasons. The main objective is to assess reasons of non-participation of older patients with cancer in clinical trials, from the physicians, patients and family caregivers' perspectives using qualitative and quantitative methods. The secondary objectives are: To investigate the social representation and construction of being "aged" from the patient, physician and family caregiver perspective (qualitative part). To compare the reasons of non-participation regarding age class (old and very old), localized versus metastatic disease and tumor site (quantitative part). To characterize the profiles of participants and non-participants to clinical trial among older patients with cancer thanks to qualitative and quantitative data. Method Quali SAGE is a French, socio-epidemiologic, multicenter prospective study that includes patients aged 70 years or over, with solid tumor (irrespective of the stage) in French hospitals.

NCT ID: NCT03225586 Recruiting - Cancer Clinical Trials

Prospective Urban Rural Epidemiology Study

Start date: January 1, 2002
Phase: N/A
Study type: Observational

To examine the impact of health determinants at the individual (e.g. health related behaviors) and societal level (e.g. environmental factors, health related policy, quality of health systems) on health outcomes (e.g. death, non-communicable disease development) across a range of socioeconomic and health resource settings. Additional components of this study will examine genetic factors for non-communicable diseases. This will be examined both through a cross sectional component, and prospectively (cohort component).

NCT ID: NCT03217864 Recruiting - Cancer Clinical Trials

Implementation of a Return Home With a Hospitalization at Home or With a Home Health Care Provider From the Services of Oncopneumology, Oncology and Hematology of University Hospital of Strasbourg

Start date: July 12, 2017
Phase: N/A
Study type: Observational

Hospitalization at home is booming. It is designed to meet the demands of patients and their families to continue care at home. It partially solves the problem of the lack of places in the "long-term care" structures and allows to respond to a desire of the health policy to reduce the lengths of stay in the hospital. Hospitalization at home is also an alternative in the management of chronic patients. Nevertheless, at the moment a certain number of requests for hospitalization at home remain unsuccessful or their implementation is complicated. In addition, the number of home health care provider has increased significantly in recent years. According to the federation of home health care provider, the number of beneficiaries increased by 1.7% in 4 years. The home health care provider would support 1,200,000 patients per year. The objective of the study is to analyze the factors participating in Implementation of a return home with a Hospitalization at home or a home health care provider during a return home project constructed with the patient and his / her relatives from the services of Oncology, oncology, hematology of the University Hospital of Strasbourg.

NCT ID: NCT03213002 Recruiting - Cancer Clinical Trials

Phase I/II Study of Oral Capecitabine and Temozolomide (CAPTEM) for Newly Diagnosed GBM

Start date: June 13, 2017
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to evaluate the safety and efficacy of administering the medication capecitabine along with temozolomide when you start your monthly regimen of oral temozolomide for the treatment of your newly diagnosed glioblastoma multiforme (GBM). Capecitabine is an oral chemotherapy that is given to patients with other types of cancer. The study will evaluate whether the dosage of 1500 mg/m2 of capecitabine is tolerable after radiation, when taken along with temozolomide. It will also try to determine if the medication capecitabine helps patients respond to treatment for a longer period of time compared to just temozolomide alone, which is the standard of care.

NCT ID: NCT03208374 Recruiting - Cancer Clinical Trials

Feasibility Information for Timely Completion of Neuroimaging Data Collection

Start date: June 27, 2017
Phase: N/A
Study type: Observational

This study will recruit approximately 5,000 patients with histologically confirmed cancer who have successfully completed MSK-IMPACT panel testing and collect information about tumor genetic results and patient exercise behavior history.

NCT ID: NCT03198052 Recruiting - Cancer Clinical Trials

PSCA/MUC1/PD-L1/CD80/86-CAR-T Cells Immunotherapy Against Cancers

Start date: July 1, 2017
Phase: Phase 1
Study type: Interventional

The third generation of CAR-T cells that target PSCA, MUC1, PD-L1, or CD80/86 have been constructed respectively and their anti-cancer function has been verified by multiple in vitro and in vivo studies.Clinical studies will be performed to test the anti-cancer function of the these individual or combination of the CAR-T cells for immunotherapy of human cancer patients with PSCA, MUC1, PD-L1, or/and CD80/86 expressions.In this phase I study, the safety,tolerance, and preliminary efficacy of the PSCA/MUC1/PD-L1/CD80/86-CAR-T cell immunotherapy on human cancers will firstly be tested.